Reference desk / Entry
Bremelanotide
Also listed as: Vyleesi
Read the scope first. Then use the note and questions to examine what the evidence can answer.
- Scoped product status
- Approved product
- Evidence label
- Randomized evidence
- Status as of
Reference fields
References for these fields are listed together in Sources.
- Product and use scope
- Vyleesi: eligible premenopausal women with distressing acquired generalized low-desire disorder.
- Route context
- Subcutaneous injection.
- Mechanism
- Melanocortin-receptor agonist.
- Evidence
- Randomized trials.
- Limitations
- Exclude medical, relationship and drug causes; not performance enhancement.
- Safety
- Uncontrolled hypertension or known cardiovascular disease: contraindicated.
A question worth making clear
Locate the places where an analysis needs an assumption in addition to recorded information. An assumption might specify how to handle an unavailable observation or which relationship a calculation treats as fixed. If such a choice appears, ask the reader beside you to explain it without using the final result as its justification. Then consider whether a reasonable alternative would change the conclusion. Separating the record from the choices used to analyze it makes disagreement easier to examine: the discussion can focus on a particular assumption and its consequences.
- Which part of the analysis depends on a choice beyond the recorded information?
- How is that choice justified without relying on the result it helps produce?
- Would a reasonable alternative assumption change the conclusion we are discussing?
Sources
Each date below belongs to the supplied source record. The references support the entry as a group.
- VYLEESI
NLM · Checked
- Kingsberg trials
PubMed · Checked